Tazasubrate

DescriptionTriglycerides (TG) are the main constituents of vegetable oil, animal fat, LDL and VLDL, and play an important role as transporters of fatty acids as well as an energy source. TG is broken down into fatty acids and glycerol, after which

Biochem/physiol Actions I-BOP is a potent thromboxane (TP) receptor agonist. I-BOP induces human platelet aggregation with an EC 50 value of 0.

A potent TP receptor agonist induces human platelet aggregation with EC₅₀ values of 0.34 and 0.17 nM at pH 7.4 and pH 6.0, respectively.

Immunotag™ Fatty Acid Synthase mouse mAb-HRP*

Immunotag™ Fatty Acid Synthase mouse mAb-HRP*

Immunotag™ Fatty Acid Synthase mouse mAb-HRP*

Immunotag™ Fatty Acid Synthase mouse mAb-HRP*

A form of tafluprost which may have increased lipid solubility compared to the free acid.

Tafolecimab (anti-PCSK9) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in

Tafolecimab (anti-PCSK9) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in

Tafolecimab (anti-PCSK9) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in

Tafolecimab (anti-PCSK9) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in